BRPI0820131A2 - Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p) - Google Patents

Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p)

Info

Publication number: BRPI0820131A2
Authority: BR; Brazil
Prior art keywords: sphingosine; oxadiazole derivatives; phosphate active; phosphate; active
Prior art date: 2007-12-21

Application number

Other languages

English (en)

Inventor

Jag Paul Heer

Ian David Wall

Thomas Daniel Heightman

David Nigel Hurst

Christopher Norbert Johnson

Emmanuel Hubert Demont

Jason Witherington

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-21

Filing date

2008-12-19

Publication date

2015-05-12

2007-12-21 Priority claimed from GB0725120A external-priority patent/GB0725120D0/en

2008-12-01 Priority claimed from GB0821918A external-priority patent/GB0821918D0/en

2008-12-19 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2015-05-12 Publication of BRPI0820131A2 publication Critical patent/BRPI0820131A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

BRPI0820131 2007-12-21 2008-12-19 Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p) BRPI0820131A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0725120A GB0725120D0 (en)	2007-12-21	2007-12-21	Compounds
GB0821918A GB0821918D0 (en)	2008-12-01	2008-12-01	Compounds
PCT/EP2008/067965 WO2009080725A1 (en)	2007-12-21	2008-12-19	Oxadiazole derivatives active on sphingosine-1-phosphate (sip)

Publications (1)

Publication Number	Publication Date
BRPI0820131A2 true BRPI0820131A2 (pt)	2015-05-12

Family

ID=40342566

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0820131 BRPI0820131A2 (pt)	2007-12-21	2008-12-19	Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p)

Country Status (28)

Country	Link
US (2)	US8222245B2 (pt)
EP (1)	EP2222669B1 (pt)
JP (1)	JP2011506569A (pt)
KR (1)	KR20100108566A (pt)
CN (1)	CN101945863B (pt)
AR (1)	AR069916A1 (pt)
AU (1)	AU2008339988B2 (pt)
BR (1)	BRPI0820131A2 (pt)
CA (1)	CA2710130A1 (pt)
CO (1)	CO6290646A2 (pt)
CR (1)	CR11579A (pt)
DK (1)	DK2222669T3 (pt)
DO (1)	DOP2010000194A (pt)
EA (1)	EA017691B1 (pt)
ES (1)	ES2434730T3 (pt)
HR (1)	HRP20130957T1 (pt)
IL (1)	IL206235A0 (pt)
MA (1)	MA31924B1 (pt)
NZ (1)	NZ585996A (pt)
PE (1)	PE20091339A1 (pt)
PL (1)	PL2222669T3 (pt)
PT (1)	PT2222669E (pt)
RS (1)	RS53038B (pt)
SI (1)	SI2222669T1 (pt)
TW (1)	TWI415847B (pt)
UY (1)	UY31570A1 (pt)
WO (1)	WO2009080725A1 (pt)
ZA (1)	ZA201003963B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102007026341A1 (de)	2007-06-06	2008-12-11	Merck Patent Gmbh	Benzoxazolonderivate
DE102007032507A1 (de)	2007-07-12	2009-04-02	Merck Patent Gmbh	Pyridazinonderivate
TWI431010B (zh)	2007-12-19	2014-03-21	Lilly Co Eli	礦皮質素受體拮抗劑及使用方法
GB0725102D0 (en) *	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
GB0725101D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
GB0725105D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
DE102007061963A1 (de)	2007-12-21	2009-06-25	Merck Patent Gmbh	Pyridazinonderivate
DE102008019907A1 (de)	2008-04-21	2009-10-22	Merck Patent Gmbh	Pyridazinonderivate
GB0807910D0 (en)	2008-04-30	2008-06-04	Glaxo Group Ltd	Compounds
DE102008028905A1 (de)	2008-06-18	2009-12-24	Merck Patent Gmbh	3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
EA019320B1 (ru)	2008-12-22	2014-02-28	Мерк Патент Гмбх	Новые полиморфные формы дигидрофосфата 6-(1-метил-1h-пиразол-4-ил)-2-{3-[5-(2-морфолин-4-илэтокси)пиримидин-2-ил]бензил}-2h-пиридазин-3-она и способы их получения
GB0910674D0 (en)	2009-06-19	2009-08-05	Glaxo Group Ltd	Novel compounds
WO2011028927A1 (en) *	2009-09-04	2011-03-10	Allergan, Inc.	Selective sphingosine-1-phosphate receptor antagonists
WO2012154760A1 (en)	2011-05-10	2012-11-15	Gilead Sciences, Inc.	Fused heterocyclic compounds as sodium channel modulators
CN102250035A (zh) *	2011-06-10	2011-11-23	北京富卡生物技术有限公司	二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途
UY34171A (es)	2011-07-01	2013-01-31	Gilead Sciences Inc	Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (pt)	2011-07-01	2018-04-28
RU2543485C2 (ru) *	2013-02-26	2015-03-10	Андрей Александрович Иващенко	Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
CN104844535A (zh) *	2014-02-13	2015-08-19	吉利德科学公司	用于制备稠合杂环离子通道调节剂的方法
UY36274A (es)	2014-08-20	2016-02-29	Bristol Myers Squibb Company Una Corporación Del Estado De Delaware	Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
WO2016075239A1 (en) *	2014-11-14	2016-05-19	Boehringer Ingelheim International Gmbh	Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (sstr4) agonists
US10202368B2 (en)	2014-12-01	2019-02-12	Idorsia Pharmaceuticals Ltd.	CXCR7 receptor modulators
CN110831593A (zh) *	2017-06-14	2020-02-21	特维娜有限公司	用于调节s1p1活性的化合物及其使用方法
ES3074322T3 (en) *	2021-02-10	2026-07-20	Icahn School Med Mount Sinai	Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis
WO2023081328A1 (en) *	2021-11-04	2023-05-11	Valo Health, Inc.	Histone deacetylase 6 inhibitor compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3964478B2 (ja)	1995-06-30	2007-08-22	エーザイ・アール・アンド・ディー・マネジメント株式会社	ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JPH1180026A (ja)	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
AR035369A1 (es)	2000-11-14	2004-05-12	Smithkline Beecham Plc	Derivados de tetrahidrobenzazepina composiciones farmaceuticas que los comprenden, el uso de dichos derivados en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
EP1549640A4 (en)	2002-06-17	2008-08-06	Merck & Co Inc	1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
CN102174042B (zh)	2003-05-19	2013-09-18	Irm有限责任公司	免疫抑制剂化合物和组合物
WO2005032465A2 (en) *	2003-10-01	2005-04-14	Merck & Co., Inc.	3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7605171B2 (en)	2003-12-17	2009-10-20	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2006001463A1 (ja)	2004-06-23	2006-01-05	Ono Pharmaceutical Co., Ltd.	Ｓ１ｐ受容体結合能を有する化合物およびその用途
GB0414795D0 (en)	2004-07-01	2004-08-04	Glaxo Group Ltd	Compounds
CA2583681A1 (en)	2004-10-22	2006-05-04	Merck & Co., Inc.	2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
CA2591399C (en)	2004-12-13	2014-05-20	Ono Pharmaceutical Co., Ltd.	Aminocarboxylic acid derivative and medicinal use thereof
JP5047941B2 (ja) *	2005-03-23	2012-10-10	アクテリオンファーマシューティカルズリミテッド	免疫調節物質としての水素付加されたベンゾ（ｃ）チオフェン誘導体
WO2006100633A1 (en)	2005-03-23	2006-09-28	Actelion Pharmaceuticals Ltd	NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS
WO2006115188A1 (ja)	2005-04-22	2006-11-02	Daiichi Sankyo Company, Limited	ヘテロ環化合物
US20080306124A1 (en)	2005-06-08	2008-12-11	Rainer Albert	Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
CN101291908A (zh)	2005-08-23	2008-10-22	Irm责任有限公司	免疫抑制剂化合物和组合物
AR058221A1 (es)	2005-11-24	2008-01-23	Glaxo Group Ltd	Benzazepinas inhibidoras del factor xa, composicion farmaceutica que la comprende y su uso para fabricar un medicamento
EP2003132B1 (en) *	2006-04-03	2014-03-05	Astellas Pharma Inc.	Oxadiazole derivatives as S1P1 agonists
JP2010510251A (ja) *	2006-11-21	2010-04-02	ユニバーシティオブバージニアパテントファンデーション	スフィンゴシン＝１−燐酸受容体活性を有するベンゾシクロヘプチルアナログ
GB0725101D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
GB0725105D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
GB0725102D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
GB0725104D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds

2008
- 2008-12-18 PE PE2008002122A patent/PE20091339A1/es not_active Application Discontinuation
- 2008-12-19 BR BRPI0820131 patent/BRPI0820131A2/pt not_active IP Right Cessation
- 2008-12-19 RS RS20130479A patent/RS53038B/sr unknown
- 2008-12-19 TW TW097149553A patent/TWI415847B/zh not_active IP Right Cessation
- 2008-12-19 EP EP08864021.4A patent/EP2222669B1/en active Active
- 2008-12-19 DK DK08864021.4T patent/DK2222669T3/da active
- 2008-12-19 KR KR1020107016167A patent/KR20100108566A/ko not_active Ceased
- 2008-12-19 PL PL08864021T patent/PL2222669T3/pl unknown
- 2008-12-19 AR ARP080105590A patent/AR069916A1/es not_active Application Discontinuation
- 2008-12-19 SI SI200831050T patent/SI2222669T1/sl unknown
- 2008-12-19 EA EA201070782A patent/EA017691B1/ru not_active IP Right Cessation
- 2008-12-19 AU AU2008339988A patent/AU2008339988B2/en not_active Expired - Fee Related
- 2008-12-19 CN CN2008801273456A patent/CN101945863B/zh not_active Expired - Fee Related
- 2008-12-19 US US12/747,205 patent/US8222245B2/en not_active Expired - Fee Related
- 2008-12-19 CA CA2710130A patent/CA2710130A1/en not_active Abandoned
- 2008-12-19 UY UY31570A patent/UY31570A1/es unknown
- 2008-12-19 NZ NZ585996A patent/NZ585996A/en not_active IP Right Cessation
- 2008-12-19 HR HRP20130957AT patent/HRP20130957T1/hr unknown
- 2008-12-19 ES ES08864021T patent/ES2434730T3/es active Active
- 2008-12-19 WO PCT/EP2008/067965 patent/WO2009080725A1/en not_active Ceased
- 2008-12-19 JP JP2010538741A patent/JP2011506569A/ja active Pending
- 2008-12-19 PT PT88640214T patent/PT2222669E/pt unknown
2009
- 2009-01-28 US US12/360,886 patent/US20100174065A1/en not_active Abandoned
2010
- 2010-06-03 ZA ZA2010/03963A patent/ZA201003963B/en unknown
- 2010-06-07 IL IL206235A patent/IL206235A0/en unknown
- 2010-06-16 MA MA32926A patent/MA31924B1/fr unknown
- 2010-06-21 DO DO2010000194A patent/DOP2010000194A/es unknown
- 2010-06-21 CO CO10074455A patent/CO6290646A2/es active IP Right Grant
- 2010-07-21 CR CR11579A patent/CR11579A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN101945863A (zh)	2011-01-12
WO2009080725A1 (en)	2009-07-02
JP2011506569A (ja)	2011-03-03
SI2222669T1 (sl)	2013-10-30
CN101945863B (zh)	2013-07-03
KR20100108566A (ko)	2010-10-07
EA017691B1 (ru)	2013-02-28
AR069916A1 (es)	2010-03-03
EP2222669A1 (en)	2010-09-01
PL2222669T3 (pl)	2014-01-31
US20100174065A1 (en)	2010-07-08
DK2222669T3 (da)	2013-10-28
TW200940531A (en)	2009-10-01
EA201070782A1 (ru)	2010-12-30
TWI415847B (zh)	2013-11-21
DOP2010000194A (es)	2010-08-15
AU2008339988B2 (en)	2013-09-26
US20100273771A1 (en)	2010-10-28
HK1142062A1 (en)	2010-11-26
PT2222669E (pt)	2013-10-28
RS53038B (sr)	2014-04-30
CA2710130A1 (en)	2009-07-02
ES2434730T3 (es)	2013-12-17
ZA201003963B (en)	2011-11-30
MA31924B1 (fr)	2010-12-01
PE20091339A1 (es)	2009-09-26
NZ585996A (en)	2012-06-29
EP2222669B1 (en)	2013-08-21
CO6290646A2 (es)	2011-06-20
US8222245B2 (en)	2012-07-17
UY31570A1 (es)	2009-05-29
HRP20130957T1 (hr)	2013-11-08
AU2008339988A1 (en)	2009-07-02
CR11579A (es)	2010-09-03
IL206235A0 (en)	2010-12-30

Publication	Publication Date	Title
IL206235A0 (en)	2010-12-30	Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
CY2025012I1 (el)	2026-02-25	Δοσολογικο σχημα για εναν αγωνιστη των υποδοχεων s1p
BRPI0818457A2 (pt)	2015-04-14	Derivados de oxadiazol
BRPI1013422A2 (pt)	2016-04-05	derivados de oxadiazol
CY2018004I2 (el)	2018-09-05	Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης
DE602008005285D1 (de)	2011-04-14	Oxadiazolsubstituierte indazolderivate zur verwendung als sphingosin-1-phosphat (s1p) -agonisten
PL2003132T3 (pl)	2014-10-31	Pochodne oksadiazolu jako agoniści S1P1
DK2300013T4 (da)	2025-02-03	Phosphorderivater som kinasehæmmere
IL206278A0 (en)	2010-12-30	Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
DK2021335T3 (da)	2011-09-05	Heterocykliske forbindelser som C-FMS-kinasehæmmere
DK2300459T3 (da)	2013-09-02	Nye fenylpyrazinoner som kinasehæmmere
DK2152712T3 (da)	2012-03-26	Aminoheterocykliske fobindelser
BRPI0818161A2 (pt)	2017-05-16	composições que compreendem moduladores de receptores de esfingosina-1-fosfato (s1p)
IL200634A0 (en)	2010-05-17	Insecticidal aryl isoxazoline derivatives
DK2206710T3 (da)	2012-08-27	Indolderivater som s1p1-receptor agonister
BRPI0922464A2 (pt)	2015-08-11	Combinações de compostos ativos
DK2308869T3 (da)	2012-10-08	Azolforbindelse
BRPI0906705A2 (pt)	2015-06-30	Composto heterocíclicos
DE112007001970A5 (de)	2009-05-28	Maschinengehäuse einer elektrischen Maschine
DE112007001996A5 (de)	2009-05-28	Maschinengehäuse einer elektrischen Maschine
FIU20100142U0 (fi)	2010-03-24	Järjestely virran muodostamiseksi
DE502007003492D1 (de)	2010-06-02	Zylindrische Wirkladung
HRP20150932T1 (xx)	2015-10-09	Heterocikliäśki spojevi
BR112013013648A2 (pt)	2016-09-06	derivados de fenil oxadiazol como moduladores de receptor de esfingosina-1-fosfato(s1p)
BRPI0820831A2 (pt)	2014-12-23	Combinações de composto ativo

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2016-03-29	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.